Overview of Ostenil

Property	Description
Active ingredient	Sodium Hyaluronate
Form	Viscoelastic solution (injection)
Pharmacological class	Viscosupplementation agent
Common use	Relieving pain and improving mobility in synovial joints
Origin	Non-animal (bacterial biofermentation)

What Class of Medicine is Ostenil, and What is its Core Ingredient?

Ostenil is classified as a viscosupplementation agent, a distinct category of preparation designed to supplement the depleted natural fluid within synovial joints. Its sole active ingredient is highly purified Sodium Hyaluronate (C14H20NNaO11)n, which is the sodium salt of Hyaluronic Acid (HA).

The preparation's pharmacological class, viscosupplementation agent, denotes its primary function: to restore the essential viscoelasticity of the synovial fluid. In joints affected by degenerative changes, the joint fluid degrades, losing its natural cushioning and lubricating properties. By introducing Sodium Hyaluronate directly into the joint space via intra-articular injection, the treatment addresses this mechanical deficiency to improve joint function. This approach is distinct from oral or topical treatments.

Is Ostenil Natural, and What Form Does it Take?

The Sodium Hyaluronate used in Ostenil is a biologically derived polysaccharide that is produced via bacterial biofermentation, making it a non-animal based preparation. The product is supplied as a sterile, ready-to-use viscoelastic solution contained within a pre-filled syringe, and is manufactured by TRB Chemedica.

This non-animal origin is a key differentiating factor, minimizing the potential for allergic reactions associated with older, animal-derived formulations. The sterile, pre-filled syringe contains an isotonic aqueous solution, engineered for stability and ease of delivery. While the majority of formulations are intended for the joint space, specialized versions, such as Ostenil Tendon, exist as an intra-sheath injection to target specific tendon structures, demonstrating the versatility of this pharmacological form.

What is the General Purpose of a Viscosupplementation Agent?

The general purpose of a viscosupplementation agent is to achieve pain reduction and improved mobility by physically reinforcing the joint’s internal environment. By restoring the fluid’s capacity for shock absorption and joint lubrication, the treatment helps to protect the cartilage surfaces from friction and wear.

The clinical goal is the normalization of the joint's fluid balance and function, offering mechanical support to mitigate the symptoms of degeneration and restricted movement. This effect relates directly to the material properties of the Sodium Hyaluronate itself, which acts as a robust hydraulic cushion upon delivery. The overall outcome is aimed at supporting a patient's capacity for movement and daily activities.

What side effects are possible with Ostenil?

Possible Side Effects and Safety Information

The safety profile of this viscosupplementation agent, which contains Sodium Hyaluronate, is primarily focused on reactions occurring at the site of administration and very rare systemic events, as documented in official regulatory labeling.

Documented Adverse Reactions

Adverse reactions listed in regulatory safety summaries are mostly categorized as Very Rare, meaning they are reported to occur in less than 1 in 10,000 treated patients. The reactions are grouped into System-Organ Classes (SOCs):

System-Organ Class	Examples of Documented Reactions
General Disorders and Administration Site Conditions	Pain, feeling of heat, swelling, redness, joint effusion, discomfort, pruritus (itching)
Infections and Infestations	Joint infection (septic arthritis)
Cardiac and Vascular Disorders	Tachycardia, palpitations, hypotension, hypertension
Gastrointestinal Disorders	Nausea

The local secondary phenomena (pain, heat, swelling) are typically temporary and may occur during or immediately after the injection procedure.

Safety-Related Restrictions and Constraints

Official prescribing information includes specific safety constraints that limit use in certain populations and conditions:

Contraindications: The product is not to be used in individuals with known hypersensitivity to any of its constituents, or when the joint area is affected by infections or skin diseases.
Population-Specific Constraints: The use of the product is not recommended in children, pregnant women, or lactating women, as safety has not been established in these groups. Use is also not recommended for patients with pre-existing inflammatory joint diseases (e.g., rheumatoid arthritis).

Overdose and Emergency Response

Overdose and When to Seek Help

Due to the nature of this product as an intra-articular viscosupplementation agent, systemic overdose is generally not formally documented in regulatory prescribing information, with some official regulatory documents classifying the overdose section as "Not Applicable." The profile focuses instead on the risk of rare, severe systemic complications or local phenomena tied to over-volume administration.

Documented Manifestations and Emergency Action

Manifestation Type	Regulatory Action Required
Severe Systemic Allergic Reactions	Seek immediate medical attention for signs of a life-threatening systemic allergic reaction, including hives, difficult breathing, or swelling of the face, lips, tongue, or throat. These rare events may be accompanied by transient hypotension.
Local Over-Injection Phenomena	Contact a doctor at once for new or severe pain or swelling at the injection site. This may present as exaggerated local effects, such as pronounced joint effusion, heat, or redness.

Management and Antidote Information

The regulatory documentation specifies that no specific antidote is officially documented or required for managing an overdose event. For pronounced local effusion, procedural management defined in the labeling includes the reduction of effusion by aspiration, coupled with joint rest, and the application of an an ice pack. Emergency medical care is required for all severe systemic allergic reactions, necessitating clinical observation until symptoms are fully resolved.

Therapeutic Uses of Ostenil

Therapeutic Indications and Main Uses

Ostenil is primarily used to treat symptoms associated with osteoarthritis. It is designed to manage pain and improve mobility in synovial joints, which are the moveable joints of the body containing a specialized fluid.

While most commonly applied to the knee, it is also utilized for other synovial joints, including:

The hip
The shoulder
The ankle
Small joints of the hands or feet

This treatment is typically indicated for patients experiencing joint stiffness and discomfort resulting from degenerative changes or trauma to the joint area.

Mechanism of Action and Benefits

The primary component of Ostenil is sodium hyaluronate, a substance that naturally occurs in the synovial fluid of healthy joints. In a healthy state, this fluid acts as a lubricant and a shock absorber, protecting the cartilage from mechanical wear.

Restoration of Joint Lubrication

In joints affected by osteoarthritis, the concentration and quality of natural hyaluronic acid decrease. This reduction leads to increased friction and a diminished ability to absorb impacts. The introduction of Ostenil helps to restore the viscoelastic properties of the synovial fluid, enhancing its lubricating function.

Pain Reduction and Mobility

By improving the internal environment of the joint, the treatment aims to reduce the mechanical stress on the joint surfaces. This process can lead to several benefits for the patient:

Reduction in joint pain: Decreasing friction can alleviate the chronic discomfort associated with bone-on-bone movement.
Improved joint flexibility: Better lubrication helps the joint move more smoothly, reducing the characteristic stiffness of osteoarthritis.
Enhanced physical function: With less pain and improved range of motion, patients may find it easier to perform daily activities and maintain an active lifestyle.

Protection of Cartilage

By restoring the protective cushion within the joint, the treatment helps to stabilize the joint environment. This support assists in maintaining the integrity of the remaining cartilage by distributing mechanical loads more evenly across the joint surface.

Regulatory References

US Food and Drug Administration (FDA) clearance documentation for similar devices

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Ostenil?

This section outlines the eligibility rules and restrictions for using Ostenil (Sodium Hyaluronate), based strictly on official regulatory documentation.

Absolute Contraindications

Ostenil is contraindicated and must not be used in specific populations, as explicitly stated in the product's regulatory materials:

Patients with known hypersensitivity (allergy) to Sodium Hyaluronate or any other constituent of the product.
Patients presenting with infections or skin diseases present in the area of the injection site or joint.

Restricted or Not Recommended Populations

Treatment is not recommended for certain populations due to a lack of established clinical safety and effectiveness data:

Population Group	Regulatory Status
Children	Not Recommended (Use not established)
Pregnant women	Not Recommended (Safety not established)
Lactating women	Not Recommended (Safety not established)

Comorbidity and Condition Restrictions

Use is not recommended in patients with active inflammatory joint diseases, such as rheumatoid arthritis or Bechterew disease (Ankylosing Spondylitis). Furthermore, if a patient presents with joint effusion (fluid buildup), the effusion must be reduced first before the injection is administered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory information regarding the interaction profile of Ostenil primarily concerns local compatibility with other substances intended for intra-articular administration.

Documented Interaction Contexts

Product Category / Substance	Regulatory Interaction Statement	Interaction Implication
Other Solutions for Intra-articular Use	No information on the incompatibility is available to date.	Lack of established compatibility data necessitates caution with co-administration.
Disinfectants (containing Quaternary Ammonium Salts)	Not explicitly listed in the Ostenil label, but common practice notes for Hyaluronic Acid solutions advise against use with these disinfectants.	May cause precipitation of the hyaluronic acid, preventing the intended effect.
Oral Analgesics / Anti-inflammatories	Concomitant use during the first days of treatment may be helpful for the patient.	This statement indicates that systemic pain-relief medication is not restricted and may be used to manage acute discomfort.

Official Profile Structure

Official government documents do not establish systemic drug-drug interaction mechanisms for Ostenil, given its local intra-articular administration. The interaction profile is therefore constrained to physical or chemical incompatibility at the injection site. This focus on local compatibility is a standard regulatory feature for intra-articular devices. The only restriction noted is the absence of data regarding incompatibility with other intra-articular solutions, which informs the practice of single-agent injection. The allowance for concurrent use of oral pain relievers suggests no systemic pharmacokinetic interaction of concern is known or documented in official sources.

Mechanism of Action

Ostenil's mechanism of action involves the introduction of exogenous sodium hyaluronate into the synovial space. This intervention is essential for maintaining adequate hydrodynamic damping and lubrication. The action is centered on viscoelastic restoration of the synovial fluid properties, crucial for its role in mitigating mechanical stress transmission within the joint.

Viscoelastic Restoration of Synovial Fluid

Sodium hyaluronate acts by supplementing the intra-articular fluid volume, restituting the viscoelastic properties of the synovial fluid. This increases fluid tenacity and elasticity, minimizing the coefficient of friction between articular surfaces and contributing to efficient shock absorption.

Modification of Boundary Layer Mechanics

The hyaluronate molecules form a polymeric layer that interfaces with the articular cartilage and synovial intima, altering boundary layer mechanics. Furthermore, the mechanism influences local cell signaling pathways, potentially stimulating resident synoviocytes to increase endogenous hyaluronate synthesis.

Modulation of Local Microenvironment

The biomechanical and biochemical modification of the synovial fluid modulates local inflammatory cell activity and reduces mechanoreceptor excitation. This involves regulating the environment by mitigating friction-induced irritation and may influence the activity of specific inflammatory mediators, contributing to local tissue state modification.

Dosage and Administration Information

Ostenil is a viscoelastic solution containing sodium hyaluronate, which is administered exclusively by intra-articular injection directly into the joint cavity. This process must be carried out by a qualified healthcare professional. The injection procedure involves administering the entire content of one pre-filled syringe (20 mg/2.0 ml) per affected joint.

Official Administration Protocol

The standard official dosing schedule requires an injection to be given once a week for a full course of three to five injections. Multiple joints may be treated at the same time during the course. Treatment cycles may be repeated as required by the patient’s condition.

Administration Detail	Official Requirement
Route	Intra-articular (into the joint cavity)
Dose	20 mg/2.0 ml (one pre-filled syringe)
Frequency	Once a week
Total Course	3 to 5 injections

Procedural and Safety Notes

Before the injection, the contents of the pre-filled syringe are sterile as long as the packaging remains intact. The healthcare provider must prepare the syringe by attaching a suitable needle (e.g., 18 to 25 G) and removing any air bubbles. The injection must be accurately placed into the joint cavity, sometimes requiring imaging control. In cases where the joint has excess fluid (joint effusion), the effusion should be reduced first before starting the treatment. The solution is strictly for single use; any unused portion must be discarded immediately after opening to maintain sterility and prevent infection. The use of Ostenil is not recommended for children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levetiracetam

Evidence for use in Partial-Onset Seizures

Levetiracetam was studied for its use in patients experiencing partial-onset seizures, which are conditions characterized by fluctuating or episodic manifestations. Research has examined short-term symptom changes primarily through randomized controlled trials (RCTs). Studies included populations who were receiving one or two other concurrent antiepileptic drugs. Researchers monitored outcomes describing episodic or acute changes, specifically measuring changes in seizure frequency and the proportion of patients who were measured as having an absence of seizures during the defined study periods.

Findings describe patterns observed in the studies over the short-term treatment intervals. Studies reported how symptoms evolved in the observed populations, noting changes in the frequency of episodes measured during the study period compared to a placebo group. However, long-term effects are not fully established. Follow-up durations were limited in the controlled phase of the research, meaning there is limited information for long-term outcomes and the stability of the observed patterns over time.

Evidence for use in Myoclonic Seizures

Levetiracetam was evaluated in adolescents and adults with Juvenile Myoclonic Epilepsy (JME), a condition associated with acute or disruptive episodes. The studies monitored outcomes describing episodic or acute changes, specifically measuring the proportional change in weekly myoclonic seizure frequency and the proportion of patients who experienced a change meeting a defined threshold. Limited data are available to fully describe outcomes beyond the 16-week treatment phase. The existing studies provide limited insight into research exploring myoclonic seizures outside the specific context of JME.

Evidence for use in Primary Generalized Tonic-Clonic Seizures

Levetiracetam was studied for Primary Generalized Tonic-Clonic (PGTC) seizures in adolescents and adults with Idiopathic Generalized Epilepsy (IGE). The research examined outcomes describing episodic or acute changes, specifically measuring the proportional change in weekly PGTC seizure frequency. Evidence is limited for long-term outcomes, as follow-up durations were limited in these studies. The data collected provides limited insight into research exploring other generalized seizure types beyond PGTC seizures in this population.

What is still uncertain about Levetiracetam

Studies contribute to the broader evidence landscape, but certainty remains low regarding various aspects of treatment. Evidence is limited and variable across all indications for long-term outcomes. Sample sizes were modest in certain pediatric cohorts and specific patient subgroups. Comparative research is lacking to provide a full comparison of levetiracetam with other available treatments. Research is ongoing.

Key Studies & References

Efficacy and Tolerability of Levetiracetam Add-On Therapy in Patients with Refractory Idiopathic Generalised Epilepsy (Includes combined data for Myoclonic and PGTC seizures)

Frequently Asked Questions (FAQ)

Common questions about Ostenil (FAQ)

Q: Do you need a prescription for Ostenil injections?

As an intra-articular injection, Ostenil must be administered exclusively by a qualified healthcare professional. Because the injection requires professional handling and accurate placement within the joint cavity, this requirement for professional administration generally aligns with products requiring restricted access, though local dispensing rules may vary.

Q: Is Ostenil available as a pill or only as an injection?

Ostenil is available only as a sterile, ready-to-use viscoelastic solution contained within a pre-filled syringe. It is designed only for direct injection into the joint space (intra-articular injection) and is not available in an oral (pill) form.

Q: What conditions, besides knee pain, is Ostenil used to treat?

Official product information indicates that Ostenil is used to relieve pain and improve mobility in degenerative and traumatic changes of synovial joints—the joints containing fluid that allows movement. This includes the knee, but also other large joints like the hip and shoulder.

Q: Can I exercise right after getting an Ostenil injection?

Regulatory guidance advises managing possible local reactions, such as temporary pain or swelling, that may occur immediately after the injection procedure. While official documents don't provide a universal activity schedule, the managing healthcare professional typically gives specific post-injection activity considerations to help manage temporary local discomfort.

Q: Why is Ostenil sometimes called a 'viscosupplement'?

Ostenil is classified as a viscosupplementation agent. It is given this name because its core function is to supplement the natural joint fluid to restore its viscoelasticity—meaning its ability to act both as a thick fluid (viscous) and a shock absorber (elastic).

Q: Are there different versions of Ostenil (e.g., Mini, Plus)? What's the difference?

Yes, there are different formulations within the product family, such as Ostenil, Ostenil Plus, and Ostenil Mini. These differences relate to the specific concentration of sodium hyaluronate, whether other ingredients (like Mannitol) are included, and are associated with different recommended administration schedules.

Q: Is it possible to have multiple joints treated with Ostenil at the same time?

Official documents note that several joints may be treated during the same course. The decision to treat multiple joints is part of the clinical assessment performed by the healthcare professional.

Q: What is the difference in how Ostenil and PRP (Platelet-Rich Plasma) work?

Ostenil’s mechanism of action involves supplementing the joint fluid with Sodium Hyaluronate to restore lubrication and shock absorption. PRP is not included in Ostenil’s official regulatory information and works through a distinct mechanism focused on elements from the patient’s own blood.

Q: Can Ostenil be used in younger patients with sports injuries?

Ostenil is indicated for degenerative and traumatic changes in synovial joints. However, official regulatory documents state that use is not recommended in children. Consultation with a specialist can determine the appropriateness of treatment for younger adults with traumatic injuries.

Q: Does having an Ostenil injection hurt the joint in the long run?

Official documents report rare temporary local reactions and very rare serious infections, but they do not indicate that the injection causes damage to the joint in the long term. Any concerns about the health of the joint should be addressed by a healthcare professional.

Q: Can Ostenil help with joint stiffness as well as pain?

Yes. The official indications for Ostenil state that it is used to relieve pain and improve mobility in synovial joints. The improvement in mobility helps to address the symptoms of joint stiffness.

Q: Are there any dietary restrictions when getting Ostenil injections?

No. Regulatory documents for Ostenil do not list or recommend any specific dietary restrictions related to its use.

Q: Is Ostenil considered a biological therapy?

Ostenil is classified as a Class III Medical Device used for viscosupplementation. While the active ingredient is derived from a biological process (bacterial biofermentation), it is officially classified as a Medical Device, not a biological drug.

Q: What is the main difference between Ostenil and cortisone shots?

Ostenil is a viscosupplementation agent that works by restoring the lubricating and shock-absorbing properties of the joint fluid. Cortisone is a type of corticosteroid (steroid) that works through a different mechanism, primarily by reducing local inflammation.

Q: How long does the effect of an Ostenil shot usually last?

Official documents indicate that the beneficial effects from a full treatment course may last for six months or more. The treating professional can advise on when a repeat course of treatment may be appropriate.

Q: Does Ostenil interact with common pain relievers like paracetamol or ibuprofen?

Regulatory documents state that using oral pain relievers and anti-inflammatory drugs alongside Ostenil may be helpful, especially in the first days after the injection, and is not restricted.

Q: Is it possible for Ostenil to interact with blood thinners?

Due to its local action when injected directly into the joint space, official regulatory documents do not provide information on systemic drug-drug interaction mechanisms with oral medications like blood thinners.

Q: Are the side effects of Ostenil generally mild or serious?

The majority of adverse reactions reported are local and temporary, such as pain, heat, or swelling at the injection site, which are typically considered mild. However, very rare serious events, such as a joint infection (septic arthritis), have been reported.

Q: Does Ostenil completely cure osteoarthritis, or just manage symptoms?

Ostenil is indicated to relieve pain and improve mobility, which represents the management of the symptoms associated with the degenerative changes of osteoarthritis. It is not listed in official documents as a cure for the underlying condition.

Q: Can Ostenil be used in combination with physical therapy?

Regulatory documents do not mention physical therapy as an interaction concern, suggesting that its use is compatible as part of an overall treatment plan focused on rehabilitation.

Q: Is Ostenil suitable for all stages of osteoarthritis?

Ostenil is indicated for the pain and restricted mobility of degenerative joint disease. However, official documents state that its use is not recommended if a patient has active inflammatory joint diseases, such as rheumatoid arthritis, or has an infection in the joint area.

How should Ostenil be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal protocols for Ostenil are strictly governed by regulatory labeling to ensure safety and integrity.

Requirement Type	Official Instructions
Temperature & Environment	Store at room temperature, not exceeding 25°C. Do not refrigerate or freeze.
Packaging & Handling	Keep the product in the original, intact sterile pack. Do not use if the syringe or packaging is damaged. This product is for single use only; do not resterilize.
Stability	Use immediately after opening the sterile pack. Any unused solution must be discarded right away.
Accessibility	The product must be stored out of the reach of children.
Disposal	The used pre-filled syringe must be disposed of as a sharp. Place it immediately in a sharps disposal container. Do not discard the syringe in household trash; follow local community guidelines for controlled waste disposal.

Ostenil